STOCK TITAN
  1. Home
  2. Sec-filings
  3. APRE
  4. [Form 4] Aprea Therapeutics, Inc. Insider Trading Activity

Aprea Therapeutics (APRE) director granted RSUs and stock options in new equity awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aprea Therapeutics director Marc Duey reported new equity awards rather than market trades. He received 3,135 restricted stock units on June 16, 2026, which are scheduled to vest and settle in common stock on June 16, 2027, subject to his continued service on the board and potential acceleration under certain conditions.

Duey was also granted stock options for 12,555 shares of common stock at an exercise price of $0.7293 per share, expiring on June 16, 2036. These options vest in full on June 16, 2027, subject to continued board service and similar acceleration terms. After these awards, he directly holds 259,290 common shares. An additional 602 shares are held indirectly by his spouse, and he disclaims beneficial ownership of those securities.

Positive

  • None.

Negative

  • None.
Insider Duey Marc
Role null
Type Security Shares Price Value
Grant/Award Stock Options (Right to Buy) 12,555 $0.00 --
Grant/Award Common Stock 3,135 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Stock Options (Right to Buy) — 12,555 shares (Direct, null); Common Stock — 259,290 shares (Direct, null); Common Stock — 602 shares (Indirect, By Spouse)
Footnotes (1)
  1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
Restricted stock units granted 3,135 units Granted June 16, 2026; vest June 16, 2027
Stock options granted 12,555 options Granted June 16, 2026; derivative award
Option exercise price $0.7293 per share Stock options on common stock
Option expiration date June 16, 2036 Stock options term
Direct common shares after grant 259,290 shares Total direct holdings following transactions
Indirect common shares by spouse 602 shares Held by spouse; beneficial ownership disclaimed
restricted stock units financial
"These shares represent restricted stock units which were granted on June 16, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"security_title: Stock Options (Right to Buy) with 12,555.0000 shares"
beneficial ownership financial
"The reporting person disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 of the Securities Exchange Act of 1934 regulatory
"for purposes of Section 16 of the Securities Exchange Act of 1934"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Duey Marc
(Last)(First)(Middle)
3805 OLD EASTON ROAD
(Street)
DOYLESTOWN PENNSYLVANIA 18902
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Aprea Therapeutics, Inc. [ APRE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/16/2026A3,135(1)A$0.00259,290D
Common Stock602IBy Spouse(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$0.729306/16/2026A12,555 (3)06/16/2036Common Stock12,555$0.0012,555D
Explanation of Responses:
1. These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
2. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
3. The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
/s/ John Hamill, as Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Aprea Therapeutics (APRE) report for Marc Duey?

Aprea Therapeutics reported that director Marc Duey received equity awards, not open-market trades. He was granted 3,135 restricted stock units and stock options for 12,555 shares, both dated June 16, 2026, as part of his board compensation.

How many restricted stock units did Marc Duey receive from Aprea Therapeutics (APRE)?

Marc Duey received 3,135 restricted stock units from Aprea Therapeutics. These units were granted on June 16, 2026 and are scheduled to vest and settle in common stock on June 16, 2027, contingent on his continued service on the board.

What are the key terms of Marc Duey’s stock option grant at Aprea Therapeutics (APRE)?

Marc Duey received stock options covering 12,555 Aprea Therapeutics common shares at an exercise price of $0.7293 per share. The options were granted on June 16, 2026, vest in full on June 16, 2027, and expire on June 16, 2036.

When do Marc Duey’s Aprea Therapeutics (APRE) equity awards vest?

Both Marc Duey’s 3,135 restricted stock units and his stock options for 12,555 shares are scheduled to vest in full on June 16, 2027. Vesting is conditioned on his continued service on Aprea Therapeutics’ board of directors through that date.

How many Aprea Therapeutics (APRE) shares does Marc Duey hold after these awards?

After the June 16, 2026 awards, Marc Duey directly holds 259,290 shares of Aprea Therapeutics common stock. An additional 602 shares are held indirectly by his spouse, for which he disclaims beneficial ownership under Section 16 rules.

Are Marc Duey’s recent Aprea Therapeutics (APRE) transactions open-market buys or sells?

Marc Duey’s recent Form 4 shows compensation-related grants, not market trades. He acquired 3,135 restricted stock units and 12,555 stock options as director awards, with no open-market purchase or sale transactions reported in this filing.